Lucid Diagnostics Inc. (LUCD)
After hours:
| Previous Close | 0.8291 |
| Open | 0.8200 |
| Bid | 0.7784 x 100 |
| Ask | 0.8173 x 100 |
| Day's Range | 0.8100 - 0.8342 |
| 52 Week Range | 0.6300 - 1.5800 |
| Volume | |
| Avg. Volume | 170,565 |
| Market Cap | 39.974M |
| Beta (5Y Monthly) | 1.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2100 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.71 |
PR NewswireLucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it held its inaugural educational session and #CheckYourFoodTube Precancer Testing Event targeting former NFL players in Cincinnati, Ohio.
- PR Newswire
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), announced that the American Foregut Society's (AFS) 2024 Annual Meeting, being held from September 26-28, 2024 at the Gaylord Rockies Resort & Convention Center in Aurora, CO, will be highlighting its EsoGuard® Esophageal DNA Test for early detection of esophageal precancer to conference participants.
PR NewswirePAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that, as part of its efforts to regain compliance with Nasdaq's listing requirements, Lucid Diagnostics (Nasdaq: LUCD) ("Lucid") will be deconsolidated from PAVmed's financial statements. As a result, PAVmed will no longer report consolidated financials reflecting Lucid's operating losses. PAVme
